Robert Stein - Protagenic Therapeutics Director
| PTIX Stock | USD 1.28 0.10 7.25% |
Director
Dr. Robert B. Stein, M.D. Ph.D. is Director of the Company. He is Chief Scientific Officer of Agenus Inc. Dr. Robert B. Stein leads Agenus Research, Preclinical Development and Translational Medicine functions. He helps shape clinical development strategy for vaccines and adjuvants. Additionally, hes leading integration of the 4Antibody acquisition, which includes the companys fully human antibody drug discovery and optimization technology platform, and portfolio of immune checkpoint antibody programs. Over his 30 years of experience in the biopharmaceutical industry he played a pivotal role in bringing to the market Sustiva, Fablyn, Viviant, PanRetin, TargRetin, Promacta and Eliquis. Prior to joining Agenus he held executive management positions at Ligand Pharmaceuticals, DuPont Merck, Incyte Pharmaceuticals, Roche Palo Alto and KineMed. Dr. Stein began his career at Merck, Sharp and Dohme. He holds an MD and a PhD in Physiology Pharmacology from Duke University since 2016.
| Age | 65 |
| Tenure | 8 years |
| Address | 149 Fifth Avenue, New York, NY, United States, 10010 |
| Phone | 212 994 8200 |
| Web | https://www.protagenic.com |
Protagenic Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4578) % which means that it has lost $0.4578 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9448) %, meaning that it created substantial loss on money invested by shareholders. Protagenic Therapeutics' management efficiency ratios could be used to measure how well Protagenic Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.21 in 2024. Return On Capital Employed is likely to rise to -1.17 in 2024. At this time, Protagenic Therapeutics' Total Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 12 M in 2024, whereas Total Assets are likely to drop slightly above 4.1 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Welch | Rezolute | 56 | |
| Zhengfei Lu | Sino Biopharmaceutical Ltd | 53 | |
| Hong Lu | Sino Biopharmaceutical Ltd | 47 | |
| Samir Patel | Rezolute | 46 | |
| Robert Dixon | AN2 Therapeutics | 60 | |
| John Short | AN2 Therapeutics | 70 | |
| Wenyu Xia | Sino Biopharmaceutical Ltd | 48 | |
| William Ryan | AN2 Therapeutics | 71 | |
| Tae Kim | Rezolute | 34 | |
| Antonio Neri | AN2 Therapeutics | 49 | |
| Ling Zhang | Sino Biopharmaceutical Ltd | 43 | |
| Gilbert Labrucherie | Rezolute | 44 | |
| Ramiro Peru | AN2 Therapeutics | 60 | |
| Kerry Clark | AN2 Therapeutics | 63 | |
| Bahija Jallal | AN2 Therapeutics | N/A | |
| YoungJin Kim | Rezolute | N/A | |
| George Schaefer | AN2 Therapeutics | 70 | |
| Sheng Chen | Sino Biopharmaceutical Ltd | 37 | |
| Will Feest | AN2 Therapeutics | N/A | |
| Lu Zhang | Sino Biopharmaceutical Ltd | 61 | |
| Zhoushan Tian | Sino Biopharmaceutical Ltd | 59 | |
Management Performance
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.46 |
Protagenic Therapeutics Leadership Team
Elected by the shareholders, the Protagenic Therapeutics' board of directors comprises two types of representatives: Protagenic Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protagenic. The board's role is to monitor Protagenic Therapeutics' management team and ensure that shareholders' interests are well served. Protagenic Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protagenic Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert MD, Chief Director | ||
| Gregory Ekizian, Independent Director | ||
| Robert Stein, Director | ||
| Garo Armen, Chairman of the Board | ||
| Brian Corvese, Independent Director | ||
| MD CFA, CFO Secretary | ||
| Khalil Barrage, Independent Director | ||
| David Lovejoy, Scientific Officer | ||
| Andrew Slee, Chief Officer | ||
| Alexander Arrow, Acting CFO | ||
| Joshua Silverman, Director |
Protagenic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protagenic Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 1.62 M | ||||
| Shares Outstanding | 4.44 M | ||||
| Shares Owned By Insiders | 21.83 % | ||||
| Shares Owned By Institutions | 7.96 % | ||||
| Number Of Shares Shorted | 9.83 K | ||||
| Price To Earning | 9.43 X | ||||
| Price To Book | 1.74 X | ||||
| EBITDA | (4.5 M) |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protagenic Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagenic Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Protagenic Stock analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is Protagenic Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagenic Therapeutics. If investors know Protagenic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagenic Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.15) | Return On Assets (0.46) | Return On Equity (0.94) |
The market value of Protagenic Therapeutics is measured differently than its book value, which is the value of Protagenic that is recorded on the company's balance sheet. Investors also form their own opinion of Protagenic Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagenic Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagenic Therapeutics' market value can be influenced by many factors that don't directly affect Protagenic Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagenic Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagenic Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagenic Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.